Attracting 60,000 Adalimumab Patients Aids Biogen
Biogen’s Total Year-To-Date Biosimilar Sales Top $500m
Executive Summary
Rolling out its Imraldi adalimumab brand across Europe is maintaining growth in Biogen’s biosimilars franchise as sales of its Benepali etanercept drug slip back.
You may also be interested in...
Samsung Bioepis Adds To Biogen Collaboration
Samsung Bioepis and Biogen have agreed a marketing deal for ‘next generation’ biosimilars aflibercept and ranibizumab in the US, Canada, Europe, Japan and Australia, as well as providing an option for Biogen to extend its existing deal to market anti-TNF biosimilars adalimumab, etanercept and infliximab in Europe and adding a further option for rights to sell these three biosimilars in China.
No Single Biosimilars Model Fits Europe, Says Samsung Bioepis’ Ko
In the second part of an exclusive interview with Generics Bulletin, Samsung Bioepis CEO Christopher Hansung Ko sets out the firm’s strategy in Europe, as well as the importance of Brazil and China to its future plans.
Samsung Bioepis’ Adalimumab Has A Longer Life Out Of The Fridge
Samsung Bioepis’ Imraldi adalimumab biosimilar has been granted a European label update that approves the product to be stored in non-refrigerated conditions for up to 28 days.